Dergiler / Van Tıp Dergisi / 2019 / Cilt: 26 - Sayı: 2

Treatment Outcomes of HER-2 Positive Metastatic Breast Cancer Patients Treated with Pertuzumab in the First Line Setting- Real Life Experience

Birinci Basamakta Pertuzumab ile Tedavi Edilen Her-2 Pozitif Metastatik Meme Kanserli Hastaların Sonuçları: Gerçek Yaşam Verisi

Sayfa
254–260
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Even with a small sample size, our results confirm that pertuzumab + trastuzumab + docetaxel combination therapy in the first line setting for HER2 positive mBC patients is the standard of care, with acceptable toxicity profile.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Pertuzumab, a new recombinant humanized monoclonal antibody, has been developed to inhibit the formation of HER2:HER3 heterodimerization.
📊
Temel Bulgular & Veri:The clinical benefit of pertuzumab therapy in HER2 positive metastatic Breast Cancer (mBC) patients in the first-line setting has been shown in previous phase III studies.
💡
Sonuç & Katkı:Conclusion: Even with a small sample size, our results confirm that pertuzumab + trastuzumab + docetaxel combination therapy in the first line setting for HER2 positive mBC patients is the standard of care, with acceptable toxicity profile.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Pertuzumab, a new recombinant humanized monoclonal antibody, has been developed to inhibit the formation of HER2:HER3 heterodimerization. The clinical benefit of pertuzumab therapy in HER2 positive metastatic Breast Cancer (mBC) patients in the first-line setting has been shown in previous phase III studies. Herein we aimed to analyze the efficacy and toxicity profile of pertuzumab in patients with HER2 positive mBC. Materials and Methods: This was a retrospective study of 28 patients with mBC followed from two different centers in Turkey. All patients were treated with pertuzumab in the first line setting, with a combination including trastuzumab and docetaxel. Treatment outcomes along with drug efficacy and safety were retrospectively analyzed. Results: At a median follow-up time of 10.1 (2.4-25.2) months, among the 28 patients, 1 (3.6%) case of death and 2 (7.1%) cases of progression occurred. The median age was determined as 47 (18-74) years. Excluding 1 patient, all had (96.4%) de-novo metastatic disease at presentation. The median number of treatment cycles was 7 (4 - 12) for docetaxel, 18 (4 - 35) for pertuzumab + trastuzumab, and 10 (1 - 29) for the maintenance therapy (pertuzumab + trastuzumab). The most common side effects were fatigue (75%) and arthralgia/myalgia (64.3%). Grade 3 or 4 toxicity was observed to be very infrequent as follows: neutropenia; grade 3 in 4 (14%) patients and grade 4 in 1 (3.6%) patient, neuropathy; grade 3 in 5 (17.8%) patients. Conclusion: Even with a small sample size, our results confirm that pertuzumab + trastuzumab + docetaxel combination therapy in the first line setting for HER2 positive mBC patients is the standard of care, with acceptable toxicity profile.

Abstract

Amaç: Pertuzumab HER2:HER3 heterodimerizasyon oluşumunu inhibe eden, yeni geliştirilen bir rekombinant humanize monoklonal antikordur. Daha önce yapılan faz III çalışmalarda, HER2 pozitif metastatik Meme Kanseri (mMK) hastalarında pertuzumabın klinik faydası gösterilmiştir. Biz de bu çalışmada HER2 pozitif mMK'li hastalarda pertuzumabın etkinlik ve toksisite profilini analiz etmeyi amaçladık. Gereç ve Yöntemler: Çalışmamızda Türkiye'deki iki farklı merkezden takip edilen 28 mMK hastasının retrospektif verileri incelenmiştir. Tüm hastalar birinci basamakta pertuzumab ile tedavi edilmişti. İlaç etkinliği ve güvenliği ile birlikte tedavi sonuçları retrospektif olarak analiz edildi. Bulgular: Ortanca 10.1 (2.4-25.2) ay takip süresince, toplam 28 hastada, 1 (%3.6) ölüm vakası ve 2 (%7.1) progresyon vakası gerçekleşti. Ortanca yaş 47 (18-74) olarak saptandı. Bir hasta hariç, hastaların hepsi (%96.4) de-novo metastatikti. Ortanca kür sayıları; dosetaksel için 7 (4 – 12), pertuzumab + trastuzumab için 18 (4 – 35) ve idame pertuzumab + trastuzumab için 10 (1 – 29) olarak saptandı. En sık görülen yan etkiler; yorgunluk (%75) ve artralji-myaljiydi (%64.3). Grade 3-4 yan etkiler çok nadir görülmekle birlikte; 4 (%14) hastada grade 3 ve 1 (%3.6) hastada grade 4 nötropeni, 5 (%17.8) hastada grade 3 nöropati görüldü. Sonuç: Az sayıda hasta içeren bir grup olsa da, sonuçlarımız pertuzumab + trastuzumab + dosetaksel kombinasyon tedavisinin birinci basamak HER2 pozitif mMK hastalarında kabul edilebilir bir toksisite profiline sahip standart bir tedavi olduğunu desteklemektedir.

🔖

Bu Makaleye Atıf Yap

HACIOĞLU, B., ŞAHİN, S. (2019). Treatment Outcomes of HER-2 Positive Metastatic Breast Cancer Patients Treated with Pertuzumab in the First Line Setting- Real Life Experience. Van Tıp Dergisi, Cilt: 26 - Sayı: 2, 254–260. https://ajindex.com/articles/334675

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pacific journal of cancer prevention: APJCP 2016; 17(3): 43-46
  2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY) 1987; 235(4785): 177- 182
  3. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proceedings of the National Academy of Sciences of the United States of America 1987; 84(20): 7159-7163
  4. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10(12): 2435-2446
  5. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. The oncologist 2009; 14(4): 320-368
  6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine 2001; 344(11): 783-792
  7. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet Oncology 2011; 12(3): 236-244
  8. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2- positive breast cancer. Journal of Clinical Oncology 2009; 27(34): 5838-5847
  9. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature reviews Cancer 2009; 9(7): 463-475
  10. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2- pertuzumab complex. Cancer cell 2004; 5(4): 317- 328
  11. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26(11): 1789-1796